Literature DB >> 22917245

Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study.

Nahlah M Almansour1, Elena Pirogova, Peter J Coloe, Irena Cosic, Taghrid S Istivan.   

Abstract

BACKGROUND: Resonant recognition model-myxoma virus (RRM-MV), a bioactive peptide analogue for myxoma virus MV-T5 protein, was computationally designed by the RRM. In this study, the anticancer effects of RRM-MV were assessed in vitro against four negative control peptides on human skin cancer and normal cells. RESULTS & DISCUSSION: The effects of RRM-MV versus negative control peptides on cells were evaluated by quantitative and qualitative assays. The RRM-MV treatment was able to induce cell death in cancer cells without triggering similar effects on normal cells. However, the negative control peptides produced no toxic effects on skin cancer and normal cells. No effects on human erythrocytes were detected when treated with all peptides.
CONCLUSION: It is suggested that the RRM can be applied to design therapeutic anticancer peptides.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22917245     DOI: 10.4155/fmc.12.98

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  3 in total

Review 1.  Emerging evidence for functional peptides encoded by short open reading frames.

Authors:  Shea J Andrews; Joseph A Rothnagel
Journal:  Nat Rev Genet       Date:  2014-02-11       Impact factor: 53.242

2.  Prediction of intrinsically disordered regions in proteins using signal processing methods: application to heat-shock proteins.

Authors:  Vuk Vojisavljevic; Elena Pirogova
Journal:  Med Biol Eng Comput       Date:  2016-04-01       Impact factor: 2.602

3.  Environmental Light and Its Relationship with Electromagnetic Resonances of Biomolecular Interactions, as Predicted by the Resonant Recognition Model.

Authors:  Irena Cosic; Drasko Cosic; Katarina Lazar
Journal:  Int J Environ Res Public Health       Date:  2016-06-29       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.